Clinical Trials Logo

Filter by:
NCT ID: NCT05582265 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinomas

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Start date: October 28, 2022
Phase: Phase 3
Study type: Interventional

A prospective, randomized, open-label, multicenter Phase 3 trial designed to compare the safety and efficacy of Tislelizumab combined with chemotherapy followed by surgery versus up-front surgery in resectable head and neck squamous cell carcinoma.

NCT ID: NCT05582174 Recruiting - Upper GI Bleeding Clinical Trials

PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers

Start date: May 18, 2023
Phase: Phase 4
Study type: Interventional

Vonoprazan (VPZ), an oral potassium-competitive acid blocker (P-CAB) has emerged as an alternative potent acid-suppressant.It has a faster onset of action in 1 day (3-5 days in PPI), and is more stable in acidic condition than PPI. While many studies compared Vonoprazan against PPI in the treatment of reflux oesophagitis, H. Pylori eradication, and gastric ulcers; thus far, there is a paucity of data on use of Vonoprazan on bleeding peptic ulcers. We perform a multicenter randomized controlled trial (RCT) to compare the efficacy of oral Vonoprazan against standard high dose PPI therapy in bleeding peptic ulcers that had received successful endoscopic haemostasis We hypothesize that in patients with bleeding peptic ulcers, the use of acid pump inhibitors Vonoprazan would not be inferior to standard treatment of a bolus plus high dose PPI intravenous infusion at preventing recurrent bleeding after endoscopic haemostasis.

NCT ID: NCT05582135 Completed - Analgesia Clinical Trials

Postoperative Analgesic Effect of Esketamine

Start date: May 5, 2021
Phase: N/A
Study type: Interventional

The aim of this study was to determine whether the addition of esketamine to morphine would improve postoperative analgesia after caesarean section. Parturients who planned for a caesarean delivery using combined spinal-epidural anaesthesia with a request for postoperative anaesthesia were randomly divided into four groups (A, B, C and D). When the surgery was completed, the parturients in groups A, B, C and D were administered 2 mg morphine, 0.25mg/kg of esketamine, 0.25mg/kg of esketamine plus 2 mg morphine sulfate and 0.25mg/kg of esketamine plus 1 mg morphine through the epidural catheters, respectively. The postoperative pain at rest, pain with movement, the number of rescue analgesics and adverse effects were evaluated for 48 h after caesarean delivery.

NCT ID: NCT05581927 Withdrawn - Brain Injury Clinical Trials

Whole-Body Hypothermia for Neonates With Hypoxic-Ischemic Encephalopathy(HIE)

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

Among term infants, hypoxic-ischemic encephalopathy due to acute perinatal asphyxia remains an important cause of brain injury in childhood. Infants with moderate encephalopathy have a 10 percent risk of death, and those who survive have a 30 percent risk of disabilities. Sixty percent of infants with severe encephalopathy die, and many, if not all, survivors are disabled. Whole-body hypothermia reduces the risk of death or disability in infants with moderate or severe hypoxic-ischemic encephalopathy.

NCT ID: NCT05581888 Active, not recruiting - Cataract Clinical Trials

Visual Performance of Functional Intraocular Lenses in Cataracts

Start date: April 1, 2020
Phase: N/A
Study type: Interventional

This is a prospective, multi-center, randomized comparative study. The purpose of the study is to evaluate and compare the postoperative visual outcomes and quality of vision of two diffractive trifocal intraocular lenses (IOLs) in patients with high myopic cataracts.

NCT ID: NCT05581303 Active, not recruiting - Clinical trials for Atherosclerotic Cardiovascular Disease

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Start date: December 14, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

NCT ID: NCT05580991 Recruiting - Solid Tumor Clinical Trials

Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

Start date: September 9, 2022
Phase: Phase 1
Study type: Interventional

To evaluate CAN1012 when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.

NCT ID: NCT05580952 Recruiting - Clinical trials for Diseases of Aortic Valve

Clinical Trial in China

Start date: October 14, 2022
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to evaluate the effectiveness and safety of the transcatheter aortic valve system in the treatment of patients with severe aortic regurgitation disease who are at high or prohibitive surgical risk.

NCT ID: NCT05580796 Recruiting - Solid Tumor Clinical Trials

KSH01-R02-101 Solid Tumors

Start date: October 11, 2022
Phase: Early Phase 1
Study type: Interventional

1. . safety and tolerance 2. . objective response rate

NCT ID: NCT05580523 Recruiting - Preeclampsia Clinical Trials

Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial

Start date: July 3, 2023
Phase: N/A
Study type: Interventional

This is a prospective, multicenter, randomized controlled, double-blind trial of three treatment arms: (1) aspirin 75 mg/day vs. (2) aspirin 150 mg/day vs. (3) aspirin 75 mg/day with metformin 1.5 g/day from the first trimester to compare the incidence of preterm preeclampsia with delivery at <37 week's gestation between the treatment arms, in order to determine the optimal therapeutic intervention for the prevention of preterm preeclampsia among Chinese women at high-risk of preeclampsia.